Brivaracetam is an anticonvulsant used to treat partial-onset seizures in patients with epilepsy by binding to synaptic vesicle protein 2A (SV2A) in the brain. It is grouped under the following drug class(es): Neurotransmitter agents and Schedule V controlled substances. Its therapeutic use is listed as anti-epileptic drugs, anticonvulsants and central nervous system (CNS) agents. The directory classifies it as a clinical API with a synthetic source/manufacturing origin. Other names for this substance include Briviact and Rikelta. It is listed as a controlled drug substance (Schedule V). Its PubChem CID is 9837243.
Brivaracetam
| CAS No | 357336-20-0 |
|---|---|
| Molecular Formula | C11H20N2O2 |
| Molecular Weight | 212.29 g/mol |
| Synonyms | (2S)-2-[(4R)-2-Oxo-4-propylpyrrolidin-1-yl]butanamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Brivaracetam is an anticonvulsant used to treat partial-onset seizures in patients with epilepsy by binding to synaptic vesicle protein 2A (SV2A) in the brain. It is grouped under the following drug class(es): Neurotransmitter agents and Schedule V controlled substances.
The listed CAS number is 357336-20-0.
The listed molecular formula is C11H20N2O2.
The listed molecular weight is 212.29 g/mol.
(2S)-2-[(4R)-2-Oxo-4-propylpyrrolidin-1-yl]butanamide.
The source lists Briviact and Rikelta.